Biotechs Continue to Underperform (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results
March 21, 2016 1:17 PM EDTLeerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's mixed PEG-PAL Ph. 3 data. In study '302, blood Phe elevated to near-baseline levels (1385.7 uM) upon discontinuation vs. pts. continuing PEG-PAL treatment (527.2 uM) (p... More
Leerink Partners Cuts Price Target on Alexion Pharma (ALXN) to $216; Reiterates Outperform
March 18, 2016 6:48 AM EDTLeerink Partners maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $216.00 (from $217.00). Conviction about the company is based on a positive outlook for Soliris [aHUS, PNH] and its potential in existing and new indications, as well as... More
